Institut De Cancerologie De L'ouest

Université D'angers

Institut National De La Sante Et De La Recherche Medicale

Institut National De La Sante Et De La Recherche Medicale (Inserm)

Olivier Coqueret

Benjamin Barre

Catherine Guette

Mario Campone

Erick Gamelin

Pedro Raro

The present invention is in the technical field of breast cancer management, and more particularly relates to the diagnosis and/or prognosing of triple-negative breast cancer (TNBC). The invention is more particularly based on the finding that specific biomarkers are abberantly expressed in patients suffering from a triple-negative breast cancer recurrence, and are highly related to the aggressiveness of this disease, and thus to survival of said patient.

Method for in vitro diagnosing and prognosing of triple negative breast cancer recurrence

The present invention is in the technical field of breast cancer management, and more particularly relates to the diagnosis of breast cancer. The invention is more particularly based on the finding that specific biomarkers (olfactomedin-4, neudesin and desmoplakin) are abberantly expressed in the blood of breast cancer patients.

Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer

The present invention provides a method for diagnosing KRAS mutations in colorectal cancers by measuring the level of OLFM4. In another aspect, the present invention relates a method of predicting the responds to a chemotherapeutic agent of a subject suffering from a colorectal cancer: according to the present invention, the by determining the OLFM4 levels. According to the present invention, the response can be predicted by determining the OLFM4 levels. This result in turn permits the design or the adaptation of a treatment of the said subject with the said chemotherapeutic agent.

Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis

Growing community of inventors

Angers, France

Olivier Coqueret